CASI Pharmaceuticals, Inc.

NasdaqCM:CASI Rapporto sulle azioni

Cap. di mercato: US$97.8m

CASI Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

CASI Pharmaceuticals' Il CEO è Wei-Wu He, nominato in Apr2019, ha un mandato di 5.33 anni. possiede direttamente 13.36% delle azioni della società, per un valore di $ 13.19M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.8 anni e 9.1 anni.

Informazioni chiave

Wei-Wu He

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO5.5yrs
Proprietà del CEO5.1%
Durata media del management2.3yrs
Durata media del Consiglio di amministrazione9.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

May 21
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

Mar 12
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Dec 18
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Sep 02
We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

May 20
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

Sep 23

CASI Pharmaceuticals Q2 2022 Earnings Preview

Aug 11

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

May 26
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Aug 14
Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

May 25
Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Mar 16
Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Wei-Wu He rispetto agli utili di CASI Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$27m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023n/an/a

-US$27m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$38m

Dec 31 2022n/an/a

-US$41m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$10mUS$322k

-US$37m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$819kUS$578k

-US$48m

Sep 30 2020n/an/a

-US$47m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$9mUS$424k

-US$46m

Sep 30 2019n/an/a

-US$43m

Jun 30 2019n/an/a

-US$42m

Mar 31 2019n/an/a

-US$32m

Dec 31 2018US$6mn/a

-US$27m

Sep 30 2018n/an/a

-US$23m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$13m

Dec 31 2017US$781kn/a

-US$11m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Wei-Wu sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.

Compensazione vs guadagni: La retribuzione di Wei-Wu è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Wei-Wu He (59 yo)

5.5yrs

Mandato

US$9,665,359

Compensazione

Dr. Wei-Wu He, Ph.D. is Chairman Emeritus at Genetron Holdings Limited since June 30, 2021 and served as its Chairman since May 2015 until June 30, 2021. He serves as Chairman and Chief Executive Officer a...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Wei-Wu He
Chairman & CEO5.5yrsUS$9.67m5.07%
$ 5.0m
Alexander A. Zukiwski
Executive VP & Chief Medical Officer7.5yrsUS$1.18mNessun dato
Wei Zhang
Senior Vice Presidentless than a yearUS$2.56m0.013%
$ 13.1k
Daniel Lang
MD, Senior VP & Chief Financial Officerless than a yearNessun datoNessun dato
Chunhua Wang
Chief Operating Officer6.6yrsNessun datoNessun dato
Wei Gao
General Counsel1.8yrsNessun datoNessun dato
James E. Goldschmidt
Chief Business Development Officerno dataNessun datoNessun dato
Hai Huang
Global Chief Commercial Officer & GM of CASI Chinaless than a yearNessun datoNessun dato
Amanda Cui
VP & Global Controllerno dataNessun datoNessun dato
Kun Qian
VP & Global Controller2.8yrsNessun datoNessun dato

2.3yrs

Durata media

56.5yo

Età media

Gestione esperta: Il team dirigenziale di CASI è considerato esperto (durata media dell'incarico 3.8 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Wei-Wu He
Chairman & CEO12.7yrsUS$9.67m5.07%
$ 5.0m
Sue Eckhardt
Member of Scientific Advisory Board18.3yrsNessun datoNessun dato
Y. Alexander Wu
Independent Director11.5yrsUS$150.50kNessun dato
Thomas Folinsbee
Independent Directorno dataNessun datoNessun dato
Ghassan Abou-Alfa
Member of Clinical Advisory Board9.3yrsNessun datoNessun dato
Zhenbo Su
Independent Director1.6yrsNessun datoNessun dato
Robert Mayer
Member of Clinical Advisory Board9.3yrsNessun datoNessun dato
Xuebo Zeng
Independent Director8.8yrsNessun datoNessun dato

9.3yrs

Durata media

57.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CASI sono considerati esperti (durata media dell'incarico 9.1 anni).